|
2021 Journal Article Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, AustraliaGasper, Harry, Ahern, Elizabeth, Roberts, Natasha, Chan, Bryan, Hughes, Brett, Kennedy, Glen, Wyld, David, Eastgate, Melissa and Lwin, Zarnie (2021). Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia. BMJ Open, 11 (5) e044655, e044655. doi: 10.1136/bmjopen-2020-044655 |
|
2021 Journal Article Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patientsKulasinghe, Arutha, Taheri, Touraj, O'Byrne, Ken, Hughes, Brett G. M., Kenny, Liz and Punyadeera, Chamindie (2021). Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patients. Frontiers in Oncology, 10 607349, 607349. doi: 10.3389/fonc.2020.607349 |
|
2021 Journal Article CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLCLeighl, Natasha B., Laurie, Scott A., Goss, Glenwood D., Hughes, Brett G.M., Stockler, Martin, Tsao, Ming-Sound, Hwang, David M., Joubert, Phillipe, Kulkarni, Swati, Blais, Normand, Joy, Anil A., Mates, Mihaela, Rana, Punam, Yadav, Sunil K., Underhill, Craig, Lee, Christopher, Bradbury, Penelope A., Hiltz, Andrea, Dancey, Janet, Ding, Keyue and Vera-Badillo, Francisco (2021). CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC. Journal of Thoracic Oncology, 17 (3), 434-445. doi: 10.1016/j.jtho.2021.10.023 |
|
2020 Journal Article CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cellsBraun, Matthias, Aguilera, Amelia Roman, Sundarrajan, Ashmitha, Corvino, Dillon, Stannard, Kimberley, Krumeich, Sophie, Das, Indrajit, Lima, Luize G., Meza Guzman, Lizeth G., Li, Kunlun, Li, Rui, Salim, Nazhifah, Jorge, Maria Villancanas, Ham, Sunyoung, Kelly, Gabrielle, Vari, Frank, Lepletier, Ailin, Raghavendra, Ashwini, Pearson, Sally, Madore, Jason, Jacquelin, Sebastien, Effern, Maike, Quine, Brodie, Koufariotis, Lambros T., Casey, Mika, Nakamura, Kyohei, Seo, Eun Y., Hölzel, Michael, Geyer, Matthias ... Bald, Tobias (2020). CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells. Immunity, 53 (4), 805-823.e15. doi: 10.1016/j.immuni.2020.09.010 |
|
2020 Journal Article Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-inNowak, Anna K, Lesterhuis, W Joost, Kok, Peey-Sei, Brown, Chris, Hughes, Brett GM, Karikios, Deme J, John, Thomas, Kao, Steven C-H, Leslie, Connull, Cook, Alistair M, Pavlakis, Nick, Briscoe, Karen, O'Byrne, Kenneth J, Karapetis, Christos S, Lam, Wei-Sen, Langford, Ailsa, Yip, Sonia and Stockler, Martin R (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 21 (9), 1213-1223. doi: 10.1016/S1470-2045(20)30462-9 |
|
2020 Journal Article Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)Grob, Jean-Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett G. M. (2020). Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). Journal of Clinical Oncology, 38 (25), 2916-2925. doi: 10.1200/JCO.19.03054 |
|
2020 Conference Publication Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancerKulasinghe, Arutha, Kapeleris, Joanna, Kenny, Liz, Hughes, Brett, Warkiani, Majid, Vela, Ian, Thiery, Jean-Paul, O'Byrne, Ken and Punyadeera, Chamindie (2020). Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer. AACR Annual Meeting 2020, Philadelphia, PA USA, 27-28 April 2020 and 22-24 June 2020. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-3384 |
|
2020 Conference Publication Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC)O'Leary, Connor, Fletcher, James, Yuile, Alexander, Xu, Wen, Ladwa, Rahul, McGrath, Margaret, Pavlakis, Nick, Hughes, Brett, McCaffery, Elizabeth and O'Byrne, Kenneth (2020). Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC). Medical Oncology Group of Australia Annual Scientific Meeting, Virtual, Australia, 14-21 August 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2020 Journal Article Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinomaTang, Kai D., Vasani, Sarju, Menezes, Lilian, Taheri, Touraj, Walsh, Laurence J., Hughes, Brett G.M., Frazer, Ian H., Kenny, Liz, Scheper, Gert C. and Punyadeera, Chamindie (2020). Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma. Cancer Science, 111 (10) cas.14585, 3854-3861. doi: 10.1111/cas.14585 |
|
2020 Journal Article Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE)Ahern, Elizabeth, Allen, Michael J., Schmidt, Andrew, Lwin, Zarnie and Hughes, Brett G. M. (2020). Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). Asia-Pacific Journal of Clinical Oncology, 17 (2) ajco.13350, e109-e116. doi: 10.1111/ajco.13350 |
|
2020 Journal Article Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingRischin, Danny, Migden, Michael R., Lim, Annette M., Schmults, Chrysalyne D., Khushalani, Nikhil I., Hughes, Brett G. M., Schadendorf, Dirk, Dunn, Lara A., Hernandez-Aya, Leonel, Chang, Anne Lynn S., Modi, Badri, Hauschild, Axel and Ulrich, Claas (2020). Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. Journal for immunotherapy of cancer, 8 (1) e000775. doi: 10.1136/jitc-2020-000775 |
|
2020 Journal Article Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Machiels, Jean-Pascal, Tao, Yungan, Burtness, Barbara, Tahara, Makoto, Licitra, Lisa, Rischin, Danny, Waldron, John, Simon, Christian, Gregoire, Vincent, Harrington, Kevin, Alves, Gustavo Vasconcelos, Figueiredo Lima, Iane Pinto, Pointreau, Yoann, M Hughes, Brett G., Aksoy, Sercan, Hetnal, Marcin, Ge, Joy Y., Brown, Holly, Cheng, Jonathan, Bidadi, Behzad and Siu, Lillian L. (2020). Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future oncology (London, England), 16 (18), 1235-1243. doi: 10.2217/fon-2020-0184 |
|
2020 Journal Article A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancerAlexander, Marliese, Pavlakis, Nick, John, Thomas, O'Connell, Rachel, Kao, Steven, Hughes, Brett G.M., Lee, Adrian, Hayes, Sarah A., Howell, Viive M., Clarke, Stephen J., Millward, Michael, Burbury, Kate, Solomon, Benjamin and Itchins, Malinda (2020). A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer, 142, 34-40. doi: 10.1016/j.lungcan.2020.01.017 |
|
2020 Journal Article Weighted activity unit effect: evaluating the cost of diagnosis-related group codingTan, Joanne Y.-A., Senko, Clare, Hughes, Brett, Lwin, Zarnie, Bennett, Richard, Power, John and Thomson, Leah (2020). Weighted activity unit effect: evaluating the cost of diagnosis-related group coding. Internal Medicine Journal, 50 (4), 440-444. doi: 10.1111/imj.14373 |
|
2020 Journal Article An occult HPV-driven oropharyngeal squamous cell carcinoma discovered through a saliva testTang, Kai Dun, Vasani, Sarju, Taheri, Touraj, Walsh, Laurence J., Hughes, Brett G. M., Kenny, Lizbeth and Punyadeera, Chamindie (2020). An occult HPV-driven oropharyngeal squamous cell carcinoma discovered through a saliva test. Frontiers in Oncology, 10 408, 408. doi: 10.3389/fonc.2020.00408 |
|
2020 Journal Article Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancerRatnayake, Gishan, Shanker, Mihir, Roberts, Kate, Mason, Robert, Hughes, Brett G. M., Lwin, Zarnie, Jain, Vikram, O'Byrne, Kenneth, Lehman, Margot and Chua, Benjamin (2020). Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 16 (1), 56-62. doi: 10.1111/ajco.13242 |
|
2020 Journal Article Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancerFong, Lawrence, Hotson, Andrew, Powderly, John D., Sznol, Mario, Heist, Rebecca S., Choueiri, Toni K., George, Saby, Hughes, Brett G. M., Hellmann, Matthew D., Shepard, Dale R., Rini, Brian I., Kummar, Shivaani, Weise, Amy M., Riese, Matthew J., Markman, Ben, Emens, Leisha A., Mahadevan, Daruka, Luke, Jason J., Laport, Ginna, Brody, Joshua D., Hernandez-Aya, Leonel, Bonomi, Philip, Goldman, Jonathan W., Berim, Lyudmyla, Renouf, Daniel J., Goodwin, Rachel A., Munneke, Brian, Ho, Po Y., Hsieh, Jessica ... Miller, Richard A. (2020). Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discovery, 10 (1), 40-53. doi: 10.1158/2159-8290.CD-19-0980 |
|
2020 Journal Article Outcomes of incidental pulmonary nodules in head-and-neck squamous cell cancer patients treated with curative intentTani, Daniel, Ladwa, Rahul, Xu, Wen, Lwin, Zarnie, Steinke, Karin and Hughes, Brett G. M. (2020). Outcomes of incidental pulmonary nodules in head-and-neck squamous cell cancer patients treated with curative intent. Journal of Head and Neck Physicians and Surgeons, 8 (1), 17-22. doi: 10.4103/jhnps.jhnps_39_19 |
|
2019 Journal Article Bilateral acute anterior uveitis: a rare ocular side effect of erlotinibChan, Sarah, Ahern, Elizabeth, Chaudhry, Sarah and Hughes, Brett (2019). Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib. BMJ case reports, 12 (12) e232868, e232868. doi: 10.1136/bcr-2019-232868 |
|
2019 Journal Article EGFR mutations in lung cancer: not all equal in the eyes of the immune system?Fong, Kwun M., Hughes, Brett G. M., Lwin, Zarnie and Yang, Ian A. (2019). EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. Annals of Translational Medicine, 7 (S8) S326, S326-S326. doi: 10.21037/atm.2019.09.132 |
